Analytical Data
-
基因名
ALCAM/CD166
- Application
-
别名
CD166; MEMD; Activated Leucocyte Cell Adhesion Molecule
-
种属
Mouse
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
Q61490
-
表达区间
Trp28~Lys527
-
分子量
60kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ALCAM (Activated Leukocyte Cell Adhesion Molecule), also known as CD166, is a member of the immunoglobulin superfamily and plays a crucial role in cell adhesion, migration, and immune response regulation. It is primarily expressed on activated immune cells and various tissues, and its interaction with integrins and other cell surface molecules is vital for leukocyte trafficking and tissue infiltration during inflammation and immune response. Studies have shown that ALCAM/CD166 is involved in tumor progression, metastasis, and the maintenance of cancer stem cells, making it a potential biomarker and therapeutic target for various malignancies. The recombinant protein of ALCAM/CD166 has been engineered to study its structure-function relationship and to elucidate its biological roles, providing insights into its mechanisms in cell signaling and adhesion processes. Research involving this recombinant protein aims to develop novel strategies for cancer immunotherapy and enhance our understanding of immune system dynamics. By investigating the interactions and pathways mediated by ALCAM/CD166, scientists hope to identify potential targets for drug development and improve treatment outcomes for patients with cancer and other immune-related disorders.
